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Background: Lipase Maturation Factor 1 (LMF1) is an ER-chaperone involved in the post-translational maturation
and catalytic activation of vascular lipases including lipoprotein lipase (LPL), hepatic lipase (HL) and endothelial
lipase (EL). Mutations in LMF1 are associated with lipase deficiency and severe hypertriglyceridemia indicating the
critical role of LMF1 in plasma lipid homeostasis. The currently available mouse model of LMF1 deficiency is based on a
naturally occurring truncating mutation, combined lipase deficiency (cld), which may represent a hypomorphic allele.
Thus, development of LMF1-null mice is needed to explore the phenotypic consequences of complete LMF1 deficiency.
Findings: In situ hybridization and qPCR analysis in the normal mouse embryo revealed ubiquitous and high-level
LMF1 expression. To investigate if LMF1 was required for embryonic viability, a novel mouse model based on a null-
allele of LMF1 was generated and characterized. LMF1-/- progeny were born at Mendelian ratios and exhibited com-
bined lipase deficiency, hypertriglyceridemia and neonatal lethality.
Conclusion: Our results raise the possibility of a previously unrecognized role for LMF1 in embryonic development, but
indicate that LMF1 is dispensable for the viability of mouse embryo. The novel mouse model developed in this study
will be useful to investigate the full phenotypic spectrum of LMF1 deficiency.
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Introduction
Lipoprotein lipase (LPL), hepatic lipase (HL) and endo-
thelial lipase (EL) are extracellular lipases involved in
plasma lipid homeostasis [1]. The secretion and activity
of these lipases depends on their post-translational mat-
uration within the endoplasmic reticulum (ER) of lipase-
expressing cells [2]. The maturation of lipases involves
folding and assembly of nascent polypeptides into cata-
lytically active homodimers, a hallmark structural feature
shared among LPL, HL and EL [3]. We have previously
demonstrated that lipase maturation factor 1 (LMF1),
an ER membrane protein, plays a critical role in lipase
maturation [4,5]. In the absence of LMF1, lipases fail* Correspondence: mpeterfy@ucla.edu
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unless otherwise stated.to mature into active enzymes, are retained within
the ER and undergo intracellular degradation [3].
Highlighting the critical role of LMF1 in lipase expres-
sion and lipid metabolism, patients with homozygous
LMF1 mutations exhibit plasma lipase deficiency and
hypertriglyceridemia [5-7].
LMF1 was initially identified as the gene disrupted by
‘combined lipase deficiency’ (cld), a naturally occurring
mutation in the mouse [5]. Homozygous cld mutant
mice exhibit deficiency in plasma LPL and HL activity, de-
velop hyperchylomicronemia and die within a few days
after birth likely due to circulatory problems [8]. While
the cld mouse model has proven valuable for the identifi-
cation of LMF1, it has several limitations. First, owing to
the presence of a recessive lethal mutation (T, brachyury)
in trans to the cld allele, “wild-type” (+/+) progeny ob-
tained from cld/+breeders are not viable, which precludes
the use of +/+littermate controls in phenotypic analysis
[9]. Second, the cld mutation arose on an outbred genetic
background harboring a variant form of chromosome 17,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mutations affecting several nearby genes [9]. Conse-
quently, phenotypes observed in cld mice cannot be un-
equivocally ascribed to LMF1 deficiency. Finally, the cld
allele produces a truncated form of LMF1 (LMF1cld) cor-
responding to ~60% of the full-length protein. As LMF1cld
is stable and correctly localizes to the ER membrane, cld
may represent a hypomorphic allele [4]. In conclusion,
characterization of the full phenotypic spectrum of LMF1-
deficiency requires the generation of mice with a null-
allele of LMF1 on an inbred genetic background.
The present study was triggered by the unexpected ob-
servation of widespread LMF1 expression in the develop-
ing mouse embryo. This observation raised the possibility
that LMF1 may be required for embryonic viability, which
may not be apparent in the hypomorphic cld model. To
test this hypothesis, we generated and characterized a
novel mouse model of complete LMF1 deficiency. Our re-
sults demonstrate that whereas LMF1 is dispensable for
the viability of mouse embryo, LMF1 deficiency is associ-
ated with lipase deficiency, hypertriglyceridemia and neo-
natal lethality. The mouse model developed in this study
will facilitate the further characterization of LMF1 in de-
velopment and metabolic regulation.
Methods
Animals
LMF1-deficient mice were generated from a gene-trapped
129/SvEvBrd Omnibank ES cell clone (OST195742) at the
Texas A&M Institute for Genomic Medicine [10]. The
trapped allele (referred to as ‘LMF1-‘ from here on) was
















36B4-r GGTGCCTCTGGA(N4). Primers used for genotyping (wild-type allele:
TG0048-5’ and TG0048-3’; gene-trap allele: LTR2 and
KO-A) are listed in Table 1. Mice were maintained on
standard laboratory chow (LabDiet 5001) in a specific
pathogen-free facility under 14:10 hour light cycle. All ani-
mal studies were approved by the Institutional Animal
Care and Use Committee at Cedars-Sinai Medical Center.
RNA analysis
In situ hybridization was carried out by Phylogeny Inc.
as described [11]. 35S-UTP-labeled sense and anti-sense
cRNA probes were generated by in vitro transcription
(Ambion) from a T7 and T3 promoter-appended PCR
product (primers T7-LMF1 and T3-LMF1 in Table 1)
representing the 5’-terminal 889 bp of the LMF1 open
reading frame. RNA and cDNA from adult tissues was pre-
pared as described previously [12] and cDNA from embry-
onic tissues was obtained from OriGene (TissueScan,
MDRT). Real-time PCR was performed using LMF1
(#4351372, Life Technologies) and GAPDH (#4352339E)
TaqMan assays (Figure 1B), or SybrGreen assays using
primers for LMF1 (p6 and p7 in Table 1) and 36B4. For
semi-quantitative RT-PCR analysis of the gene-trapped
LMF1 allele, primers (p1-p5 in Table 1) spanning multiple
exons were used as shown in Figure 2A.
Plasma assays
To obtain post-heparin plasma from newborn mice,
pups were injected intraperitoneally with 10 units of
heparin followed by decapitation and blood collection 20
minutes later. Blood was centrifuged (4,500 × g for 5









































































Figure 1 LMF1 expression in the mouse embryo. (A) In situ hybridization of embryo sections with probes representing anti-sense (middle panels)
and sense (bottom panels) transcripts of LMF1 at different days post coitus. The top panels show bright-field images of cresyl violet-stained sections.
Ad, adrenal; Br, brain; Fb, forebrain; H, heart primordium; He, heart; In, intestine; K, kidney; Li, liver; Lu, lung; M, mandibular component of branchial arch;
MO, medulla oblongata; SC, spinal cord; Sm, skeletal muscle; T, tail; To, tooth primordium; Ve, vertebrae. (B) Real-time PCR analysis of relative LMF1
expression in embryonic and adult tissues.
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of LPL and HL as described [12]. For the assessment of
plasma lipoprotein distribution, plasma obtained from
1-day-old pups was pooled and analyzed by FPLC at the
Mouse Metabolic Phenotyping Center at Vanderbilt
University School of Medicine. Because of high triglycer-
ide content and viscosity, plasma samples from LMF1-/-
animals were diluted 30-fold before FPLC analysis. At thisdilution, cholesterol concentrations in fractions could not
be reliably determined.
Data analysis
Results are shown as means ± S.E. Statistical analyses were
performed with the SigmaStat software. Two-tailed un-
paired Student’s t-test was used to compare means, and























1 2 3 4 5SA-neo-pA
p1 p2 p3 p4 p5
6
p7p6
Figure 2 Generation of LMF1-/- mice. (A) Schematic illustration of the novel LMF1 allele showing a gene-trap insertion event in intron 1.
Gray numbered boxes represent exons. The gene-trap cassette contains a splice acceptor sequence (SA), neomycin resistance gene (neo) and
polyadenylation sequence (pA). Arrowheads indicate primers (p1-p5) used for RT-PCR analysis. (B) RT-PCR analysis of LMF1 expression in neonatal
liver RNA. (C) qPCR analysis of LMF1 expression in mouse embryonic fibroblasts using primers p6 and p7 shown in panel A.
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Results
LMF1 expression in the developing mouse embryo
Previous studies indicated that LMF1 was ubiquitously
expressed in adult mouse tissues [5]. To investigate whether
the broad expression pattern of LMF1 extends to embry-
onic tissues, we performed in situ hybridization studies
in the mouse embryo at different stages of development
(Figure 1A). In E9.5 mid-gestation embryos, strong LMF1
expression was detected in rudiments of the central ner-
vous system, whereas lower mRNA levels were observed
in other tissues. LMF1 exhibited ubiquitous expression
pattern in E12.5 and E15.5 embryos with elevated levels in
skeletal muscles, cartilage of vertebrae and intestine at
late-gestation. To characterize LMF1 expression in the de-
veloping CNS further, we performed quantitative RT-PCR
analysis on RNA isolated from distinct anatomical regions
(Figure 1B). LMF1 showed uniform and ubiquitous ex-
pression in all regions and developmental stages tested.
Furthermore, LMF1 mRNA levels were comparable to
those in principal lipase-expressing adult tissues including
adipose, heart and liver (Figure 1B).
Generation of LMF1-deficient mice
To explore the role of LMF1 in embryonic viability, we
generated LMF1-deficient mice using an ES cell clone
from a gene-trap library [10]. The targeted allele harbors a
gene-trap cassette inserted within the first intron of the
LMF1 gene and is predicted to produce a truncated tran-
script containing exon 1 (Figure 1A). Indeed, transcripts
corresponding to exon 1 and the gene-trap cassettewere readily detectable in mice carrying the mutant allele
(Figure 1B, middle panel). Importantly, sequences 3’ of
exon 1 were undetectable in LMF1-/- mice (Figure 1B,
top and bottom panels). Moreover, expression of exon 6
could not be detected in LMF1-/- mouse embryonic fibro-
blasts by qPCR, which confirms the absence of LMF1
transcripts with sequences downstream of the gene-trap
integration site (Figure 1C). As exon 1 encodes the
N-terminal 64 residues of LMF1, which lacks membrane-
spanning domains and corresponds to ~10% of the full-
length polypeptide, we conclude that the gene-trap allele
most likely represents a null-allele of LMF1.
Characterization of LMF1-deficient mice
To investigate the impact of LMF1 deficiency on embry-
onic viability, we genotyped offspring obtained from het-
erozygous LMF1+/- matings. On the first day after birth,
the LMF1-/- genotype was represented at a Mendelian
ratio (i.e. 25%) among littermates indicating that LMF1
was dispensable for embryonic viability (Figure 3A).
However, the proportion of LMF1-/- pups gradually de-
creased in subsequent days and no surviving LMF1-
deficient progeny could be identified 4 days after birth
(Figure 3A).
To assess metabolic manifestations of LMF1 deficiency
in the LMF1-/- model, we characterized newborn mice
within the first day of life. LMF1-deficient neonates did
not exhibit apparent morphological defects. However,
their plasma had a milky appearance (Figure 3B), a con-
sequence of ~80-fold elevated triglyceride concentration
relative to unaffected littermates (Figure 3C). Hypertri-
glyceridemia in LMF1-/- pups was due to combined lip-
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Figure 3 Characterization of LMF1-/- mice. (A) Survival of LMF1-deficient (LMF1-/-) progeny during days 1 to 4 (d1 to d4) after birth. Dashed
line indicates Mendelian frequency (25%) of -/- genotype as expected from heterozygous matings. White numbers show total number of pups
genotyped at each time-point. Asterisks indicate significant (p < 0.05) differences from expected genotype frequencies (χ2 test). (B) White fat-cake
indicates hyperlipidemia in plasma of -/- neonates. (C) Plasma triglyceride (TG), (D) total cholesterol (TC), and (E) HDL-cholesterol (HDL-C) levels
are shown in newborn mice. (F) Plasma triglyceride and (G) cholesterol profiles were determined by FPLC analysis. (H) Post-heparin LPL and
(I) HL activities in newborn mice. *, p < 0.05.
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As expected, triglycerides were overwhelmingly associ-
ated with the chylomicron/VLDL fraction in LMF1-/-plasma (Figure 3F). Relative to wild-type and heterozygous
littermates, LMF1-/- mice also demonstrated elevated
total cholesterol (Figure 3D), but similar HDL-cholesterol
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the cholesterol profile in LMF1-/- mice, because severe
lipemia and high viscosity necessitated dilutions of sam-
ples before FPLC analysis to an extent, which prevented
the detection of cholesterol in fractions. Nonetheless,
wild-type and heterozygous mice exhibited similar plasma
cholesterol distribution (Figure 3G), where choles-
terol was predominantly associated with IDL/LDL parti-
cles, a characteristic feature of fetal murine lipoprotein
profile [13].
Discussion
In the present study, we generated a novel mouse model
of LMF1 deficiency using gene-trap mutagenesis. The
new model offers advantages over the naturally occur-
ring cld mutant mouse strain used in previous studies
[5,8]. First, in contrast to a truncating mutation in the
cld model, the gene-trap insertion characterized here
represents a definitive null-allele and allows analysis of
the full phenotypic manifestation of LMF1 deficiency.
An additional improvement of the new model over cld
is that wild-type littermates are viable, which enables
characterization of the potential phenotypic conse-
quences of heterozygous LMF1 deficiency. Finally, the
gene-trap allele is on an inbred genetic background devoid
of the confounding genetic effects associated with the cld
mutation [9].
We unexpectedly detected ubiquitous and relatively
high-level LMF1 expression in the mouse embryo. This
observation raised the possibility that in addition to its
established role in postnatal lipid metabolism, LMF1
may also be an important factor in embryogenesis.
While the role of vascular lipases during development
remains poorly characterized, embryonic expression of
all three LMF1-dependent lipases (i.e. LPL, HL and EL)
has previously been documented [14,15]. To begin to ad-
dress the potential role of LMF1 in development, we
first asked whether LMF1 deficiency affects the viability
of embryos. Our results demonstrate that despite wide-
spread expression in the developing embryo, LMF1 is
not required for embryonic survival. However, postnatal
viability of LMF1-/- pups is severely compromised, as no
surviving LMF1-deficient progeny was detected a few
days after birth. Neonatal lethality has also been observed
in cld mice [8] and is thought to be a consequence of cir-
culatory problems associated with severe hyperchylomi-
cronemia, which results from the inability to utilize
dietary fat during suckling [16]. Indeed, LMF1-/- pups ex-
hibit hypertriglyceridemia and severely diminished post-
heparin LPL and HL activities, hallmark features of LMF1
deficiency in the cld mouse model [8]. In addition to
hypertriglyceridemia, plasma concentrations of total chol-
esterol are also elevated in LMF1-/- mice, a likely conse-
quence of diminished catabolism and accumulation ofchylomicron particles due to LPL deficiency [17]. In con-
trast to total cholesterol, HDL-cholesterol levels are un-
affected in LMF1-/- plasma. At first glance, this is a
surprising observation considering the critical role of LPL
in the maturation of HDL particles [18] and severely re-
duced HDL-cholesterol in LPL-deficient mice [17,19,20].
However, in addition to LPL, LMF1-/- animals are also de-
ficient in active HL and EL [7], lipases that promote HDL
catabolism [21-23]. Thus, we propose that unaltered
HDL-cholesterol level in LMF1-/- mice is a result of com-
bined lipase deficiency involving lipases with opposite ef-
fects on HDL metabolism.
LMF1-deficient mice developed in this work will allow
in-depth investigations of the role of LMF1 in develop-
ment. However, early lethality is a limitation of this
model for metabolic studies in the adult organism. Neo-
natal lethality in LMF1-/- mice is not unique among
mouse models of hypertriglyceridemia. LPL-deficient mice
die within a few days after birth, most likely as a conse-
quence of restricted oxygen exchange in lipid-engorged
lung capillaries [17]. In contrast, hypertriglyceridemia in
mice deficient in GPIHBP1, a protein involved in the
trans-endothelial transport of LPL, is not associated with
increased mortality owing to the availability of a functional
pool of LPL in the neonatal liver [24,25]. Two strategies
have been used to rescue LPL-deficient mice from neo-
natal lethality. First, transient expression of LPL through
adenoviral gene transfer allowed a small fraction of in-
fected LPL-/- progeny to reach adulthood and enabled
metabolic characterization of LPL-deficiency [18,20,26].
We attempted a similar strategy to rescue LMF1-/- pups
using adenovirus expressing LMF1, but have been unable
to recover adult LMF1-deficient mice (unpublished obser-
vation). Importantly, LMF1-deficient mice are not only
devoid of active LPL, but also HL and EL, which may re-
sult in more severe morbidity relative to LPL-deficiency
only and explain why transient expression of LMF1 is in-
sufficient for rescue. Consistent with this explanation, HL/
EL double knock-out mice suffer from neonatal lethality
[23], which raises the possibility that combined HL/EL-de-
ficiency contributes to mortality in LMF1-/- mice. A sec-
ond strategy that has been successfully applied to rescue
LPL-/- mice is based on transgenic complementation of
LPL expression in single tissues such as heart, skeletal
muscle and liver [27-29]. A similar approach is currently
pursued in our laboratory to rescue LMF1-/- mice using a
muscle-specific LMF1 transgene [12].
In conclusion, we validated a new LMF1-deficient
mouse model by demonstrating that it recapitulates salient
phenotypes of cld mutant mice including neonatal lethal-
ity, dyslipidemia and combined lipase deficiency. At the
same time, our study also confirms that phenotypes previ-
ously observed in the cld model are genuine consequences
of LMF1 deficiency, as opposed to unrelated mutations
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our initial characterization of LMF1-/- neonates did not
reveal novel phenotypes beyond those already observed
in cld mice is consistent with the possibility that cld rep-
resents a null-allele of LMF1. However, more detailed
phenotypic characterization will be necessary before a de-
finitive conclusion can be reached. The LMF1-deficient
mouse model developed in this study will facilitate further
analysis of LMF1 function in development and metabolic
regulation.
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